MiMedx Group, Inc: valuation

MDXGNASDAQHealthcare · Surgical & Medical Instruments & Apparatus

Price

$3.18

November 16, 2026Market cap $472M

What Ploutos Investor adds for MiMedx

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 16 fiscal years, from 2010
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 21% since Oct 28, 2026, when the 10-Q these figures come from was filed ($3.95 then, $3.14 on Nov 16, 2026). The figures date from before that move.10-Q

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $3.18 (November 16, 2026), beside the median of its past fiscal years.

EV / EBIT
–
EV / Revenue
1.2
Earnings yield
–
FCF yield
4.1%
Market cap
$472M
enterprise value $352M
  • 2025
    P/E21.2
  • 2024
    P/E34.4
  • 2023
    P/E23.7

Each multiple at the closing price of the fiscal year's last trading day and the same year's figures. A year with a loss or negative free cash flow has no P/E or P/FCF.

Valuation against its own past

MDXG's P/E, P/FCF and P/B at each year-end price, from 2010 to 2022, 13 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

What today's price assumes

The discounted cash flow model run backwards: not what the company is worth, but the growth the price takes for granted.

For a buyer at $3.18 who wants 9% a year, free cash flow would need to grow by about

+4.0%a year for ten years

at 7% a year
-0.6%
at 9% a year
+4.0%
at 11% a year
+7.7%

Arithmetic on the price, not a forecast. Starts from free cash flow of $19M over the last 12 months and net cash $121M, the same growth each year for ten years, then 2.5% a year forever. Try other numbers in the DCF calculator.

DCF calculator

What is MiMedx worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
$19M
Net cash
$121M
Shares
149M
FCF, 5-year average a year
–
Revenue, 5-year average a year
+11.0%
Price
$3.18

The full analysis

What do MiMedx's filings show?

The multiples say what the market pays for MiMedx. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about MDXG's valuation

Didn't find what you were looking for?

Ask us
What is MDXG's P/FCF?

MDXG's P/FCF is 24.7: a market cap of $472M over $19M of free cash flow in the last 12 months. Put the other way, a free cash flow yield of 4.1%.

How do I work out what MDXG is worth?

With the DCF calculator: it opens with MiMedx's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.